Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Randomized Phase	STARTED	Vandetanib and Docetaxel	74
Randomized Phase	STARTED	Placebo and Docetaxel	75
Randomized Phase	Eligible & Treated	Vandetanib and Docetaxel	70
Randomized Phase	Eligible & Treated	Placebo and Docetaxel	72
Randomized Phase	COMPLETED	Vandetanib and Docetaxel	70
Randomized Phase	COMPLETED	Placebo and Docetaxel	35
Randomized Phase	NOT COMPLETED	Vandetanib and Docetaxel	4
Randomized Phase	NOT COMPLETED	Placebo and Docetaxel	40
Crossover Phase	STARTED	Vandetanib and Docetaxel	0
Crossover Phase	STARTED	Placebo and Docetaxel	37
Crossover Phase	COMPLETED	Vandetanib and Docetaxel	0
Crossover Phase	COMPLETED	Placebo and Docetaxel	37
Crossover Phase	NOT COMPLETED	Vandetanib and Docetaxel	0
Crossover Phase	NOT COMPLETED	Placebo and Docetaxel	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00880334/flow